Cetuximab
- Generic Name
- Cetuximab
- Brand Names
- Erbitux
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 205923-56-4
- Unique Ingredient Identifier
- PQX0D8J21J
- Background
Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible for regulating epithelia...
- Indication
Cetuximab indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. It is indicated for treating a recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil. It is indicated for r...
- Associated Conditions
- Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN), Metastatic Colorectal Cancer (CRC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Regionally Advanced Squamous Cell Carcinoma of the Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Associated Therapies
- -
Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study
- Conditions
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 34
- Registration Number
- NCT06547203
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab
- Conditions
- Interventions
- First Posted Date
- 2024-08-06
- Last Posted Date
- 2024-08-06
- Target Recruit Count
- 100
- Registration Number
- NCT06540326
The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-06
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 65
- Registration Number
- NCT06540261
- Locations
- 🇯🇵
Kanagawa Cancer Center, Yokohama, Kanagawa, Japan
🇯🇵Kurashiki Central Hospital, Kurashiki, Okayama, Japan
🇯🇵Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
Chemotherapy Plus EGFR Monoclonal Antibody in Patients With Liver Metastases From Colorectal Cancer With ctDNA Superselective Negative Genes
- Conditions
- Interventions
- First Posted Date
- 2024-07-08
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 33
- Registration Number
- NCT06490913
Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationProcedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyBiological: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytesBiological: CetuximabProcedure: Computed TomographyDrug: CyclophosphamideProcedure: EchocardiographyDrug: FludarabineProcedure: LeukapheresisProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition ScanProcedure: Positron Emission Tomography
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 24
- Registration Number
- NCT06447987
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity Squamous Cell Carcinoma (OCSCC).
- Conditions
- Interventions
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT06448026
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Study of RAS(ON) Inhibitors in Patients with Gastrointestinal Solid Tumors
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Revolution Medicines, Inc.
- Target Recruit Count
- 406
- Registration Number
- NCT06445062
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸UCLA Hematology/Oncology- Santa Monica, Los Angeles, California, United States
🇺🇸University of Colorado Hospital-Anschutz Cancer Pavilion, Aurora, Colorado, United States
Exploration of Therapeutic Strategies for NeoRAS Wild-type Metastatic Colorectal Cancer Based on Circulating Tumor DNA
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 1100
- Registration Number
- NCT06440902
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Melanoma and Skin Cancer Trials Limited
- Target Recruit Count
- 27
- Registration Number
- NCT06418724
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
- Conditions
- Interventions
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 31
- Registration Number
- NCT06412198
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.